Skip to content

Author

M. Tsalic

We have 1 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)

Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice and longer follow-up is needed to establish how these reductions affect overall efficacy.

H. Abdallah, Y. Owoseni, B. Baraka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.